Fracture Risk in Men With Congestive Heart Failure. Risk Reduction With Spironolactone

Journal of the American College of Cardiology

Volumn 52, Issue 2, 2008, Pages 135-138

  Carbone, Laura D ^a   Cross, Jessica D ^a   Raza, Syed H ^a   Bush, Andrew J ^a   Sepanski, Robert J ^a   Dhawan, Saurabh ^a   Khan, Bilal Q ^a   Gupta, Malini ^a   Ahmad, Khurram ^a   Khouzam, Rami N ^a   Dishmon, Dwight A ^a   Nesheiwat, Joseph P ^a   Hajjar, Mohammad A ^a   Chishti, Waqas A ^a   Nasser, Wael ^a   Khan, Mehwish ^a   Womack, Catherine R ^a   Cho, Tara ^a   Haskin, Ashley R ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

congestive heart failure; medical records; men; spironolactone

Indexed keywords

SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RISK FACTOR; VERTEBRA FRACTURE; WRIST FRACTURE;

AGED; ALDOSTERONE ANTAGONISTS; FRACTURES, BONE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPIRONOLACTONE;

EID: 45849120256     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.03.039     Document Type: Article

References (34)

1. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 345 (2001) 1689-1697
2. Farhat G.N., Strotmeyer E.S., Newman A.B., et al. Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the Health, Aging, and Body Composition Study. Calcif Tissue Int 79 (2006) 102-111
3. Nishio K., Mukae S., Aoki S., et al. Congestive heart failure is associated with the rate of bone loss. J Intern Med 253 (2003) 439-446
4. Shane E., Mancini D., Aaronson K., et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 103 (1997) 197-207
5. Chhokar V.S., Sun Y., Bhattacharya S.K., et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 111 (2005) 871-878
6. Moghetti P., Castello R., Zamberlan N., et al. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 84 (1999) 1250-1254
7. Prezelj J., and Kocijancic A. Antiandrogen treatment with spironolactone and linestrenol decreases bone mineral density in eumenorrhoeic women with androgen excess. Horm Metab Res 26 (1994) 46-48
8. Brown J.P., Josse R.G., and Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167 Suppl (2002) S1-S34
9. Seeley D.G., Browner W.S., Nevitt M.C., Genant H.K., Scott J.C., Cummings S.R., and Study of Osteoporotic Fractures Research Group. Which fractures are associated with low appendicular bone mass in elderly women?. Ann Intern Med 115 (1991) 837-842
10. Cappuccio F.P., Meilahn E., Zmuda J.M., Cauley J.A., and Study of Osteoporotic Fractures Research Group. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Lancet 354 (1999) 971-975
11. Nawroth P., Pirzer R., Fohr B., et al. Osteoporosis and cardiovascular disease-two sides of the same coin [in German]?. Med Klin (Munich) 98 (2003) 437-446
12. Tanko L.B., Bagger Y.Z., and Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 73 (2003) 15-20
13. Mantero F., and Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 61 (2000) 52-60
14. Roongsritong C., Sutthiwan P., Bradley J., Simoni J., Power S., and Meyerrose G.E. Spironolactone improves diastolic function in the elderly. Clin Cardiol 28 (2005) 484-487
15. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., and Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22 (2007) 465-475
16. Wehren L.E., Hawkes W.G., Orwig D.L., Hebel J.R., Zimmerman S.I., and Magaziner J. Gender differences in mortality after hip fracture: the role of infection. J Bone Miner Res 18 (2003) 2231-2237
17. Liberman U.A., Hochberg M.C., Geusens P., et al. Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials. Int J Clin Pract 60 (2006) 1394-1400
18. Silverman S.L., Watts N.B., Delmas P.D., Lange J.L., and Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the Risedronate and Alendronate (REAL) Cohort Study. Osteoporos Int 18 (2007) 25-34
19. Silva M.J. Biomechanics of osteoporotic fractures. Injury (2007) S69-S76 38 Suppl 3
20. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
21. Calhoun D.A. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich) 9 (2007) 19-24
22. Chhokar V.S., Sun Y., Bhattacharya S.K., et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 287 (2004) H2023-H2026
23. Macdonald H.M., New S.A., Fraser W.D., Campbell M.K., and Reid D.M. Low dietary potassium intakes and high dietary estimates of net endogenous acid production are associated with low bone mineral density in premenopausal women and increased markers of bone resorption in postmenopausal women. Am J Clin Nutr 81 (2005) 923-933
24. Kitchin B., and Morgan S.L. Not just calcium and vitamin D: other nutritional considerations in osteoporosis. Curr Rheumatol Rep 9 (2007) 85-92
25. Carmina E. Anti-androgens for the treatment of hirsutism. Expert Opin Investig Drugs 11 (2002) 357-363
26. Fried L.F., Shlipak M.G., Stehman-Breen C., et al. Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 61 (2006) 743-748
27. 3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res 19 (2004) 1221-1230
28. Colon-Emeric C.S., Pieper C.F., and Artz M.B. Can historical and functional risk factors be used to predict fractures in community-dwelling older adults?. Development and validation of a clinical tool. Osteoporos Int 13 (2002) 955-961
29. Meier C., Nguyen T.V., Center J.R., Seibel M.J., and Eisman J.A. Bone resorption and osteoporotic fractures in elderly men: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 20 (2005) 579-587
30. Mukamal K.J., Robbins J.A., Cauley J.A., Kern L.M., and Siscovick D.S. Alcohol consumption, bone density, and hip fracture among older adults: the Cardiovascular Health Study. Osteoporos Int 18 (2007) 593-602
31. Gage B.F., Birman-Deych E., Radford M.J., Nilasena D.S., and Binder E.F. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 166 (2006) 241-246
32. Uzzan B., Cohen R., Nicolas P., Cucherat M., and Perret G.Y. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40 (2007) 1581-1587
33. Jamal S.A., Browner W.S., Bauer D.C., Cummings S.R., and Study of Osteoporotic Fractures Research Group. Warfarin use and risk for osteoporosis in elderly women. Ann Intern Med 128 (1998) 829-832
34. LaCroix A.Z., Cauley J.A., Pettinger M., et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 139 (2003) 97-104